Senzime Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Philip Siberg

Chief executive officer

kr450.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.6%
Management average tenure	2.3yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

Feb 16

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

Jan 19

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Dec 23

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Nov 26

CEO

Philip Siberg (50 yo)

less than a year

Tenure

kr450,000

Compensation

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Philip Siberg	Chief Executive Officer	less than a year	kr450.00k	0.59% SEK 5.0m
Slavoljub Grujicic	Chief Financial Officer	2.3yrs	no data	0.014% SEK 117.7k
Johanna Tulkki	Chief Operating Officer	4.3yrs	no data	no data
Fredrik Norrby	Chief Technology Officer	1.3yrs	no data	no data
Rianne Waninge	Application Scientist	no data	no data	no data
Paula Treutiger	Head of Communication & Investor Relations	2.3yrs	no data	no data
Anders Selin	Executive Vice President of Sales	4.7yrs	no data	no data
Michael Noble	Vice President Global Marketing	less than a year	no data	no data
Anders Jacobson	Chief Innovation Officer	8.3yrs	no data	0.0092% SEK 77.0k
Catrin Molund	Executive Vice President of Business Development	3.3yrs	kr163.00k	no data
Johanna Faris	Head of Q/RA/S	less than a year	no data	0.00099% SEK 8.3k

2.3yrs

Average Tenure

53yo

Average Age

Experienced Management: SEZI's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Per Wold-Olsen	Chairman of the Board	less than a year	no data	no data
Goran Brorsson	Independent Director	less than a year	no data	no data
Adam Dahlberg	Vice Chairman of the Board	24.3yrs	kr210.00k	3.68% SEK 30.8m
Eva Walde	Independent Director	3.2yrs	kr210.00k	no data
Sorin Brull	Member of Clinical Advisory Board	8.3yrs	kr1.22m	2.69% SEK 22.6m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	no data	no data
Bela Fulesdi	Member of Scientific Advisory Board	no data	no data	no data
Guy Cammu	Member of Scientific Advisory Board	no data	no data	no data
Hans Boer	Member of Scientific Advisory Board	no data	no data	no data
Claude Meistelman	Member of Scientific Advisory Board	no data	no data	no data
Jennifer Hunter	Member of Scientific Advisory Board	no data	no data	no data
Casper Claudius	Member of Scientific Advisory Board	no data	no data	no data

3.2yrs

Average Tenure

67yo

Average Age

Experienced Board: SEZI's board of directors are considered experienced (3.2 years average tenure).

Senzime Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

New major risk - Financial position

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Independent Chairman recently bought kr740k worth of stock

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Less than half of directors are independent

Senzime AB (publ) Provides Earnings Guidance for 2025

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Consensus revenue estimates fall by 34%

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to kr34.00

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Will Senzime (STO:SEZI) Spend Its Cash Wisely?

Price target decreased to kr34.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: kr21.50

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

New 90-day high: kr25.80

Senzime AB (publ) Gets US Patent for OnZurf Probe

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Senzime Lands New Order from South Korea of SEK 1 Million

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Third quarter 2020 earnings released: kr0.20 loss per share

Senzime AB (publ) Announces Nomination Committee for 2021 Annual General Meeting

Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.A

Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical Company

New 90-day low: kr19.70

Senzime AB (Publ) Announces Management Changes

Senzime AB (publ) Receives Order from Switzerland